Drugs / BBM 002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05454774 | Jul 2022 → Dec 2024 overdue | hemophilia A | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBM 002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05454774 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated virus (AAV) vector” NCT05454774 ↗ |
| Route | Intravenous | “Single dose intravenous infusion of BBM 002” NCT05454774 ↗ |